Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
Extract taken from his profile on the Incanthera website:
Paul is actively involved in the design, analysis and reporting of pre-clinical and clinical pharmacokinetic studies and acts as a pharmacokinetic and drug metabolism consultant for numerous US and European pharmaceutical and biotechnology companies
'old hat' I know, but this was posted on iWeb today:
https://www.markets.iweb-sharedealing.co.uk/research-centre/market-news/article/?id=14744278&type=bsm
As with tipster. However, hci want their money, so they will continue to unload 'repayment' shares into the Market until, 1) repayment + interest is paid in cash, 2) an II picks up their unwanted, 3) they hold 'for gold' which is unlikely until they've satisfied the principal sum. AIM market is notorious, so until the data we are all waiting for is released, a 'fluid' sp is all we can expect (ofcourse,all imo). A great buying opportunity for the some of us.
Https://www.verywellhealth.com/definition-of-first-line-treatment-2249101
BV, extract from the rns "In addition to the excellent safety profile being observed for AVA6000, clear signs of efficacy have now been confirmed. One patient with soft tissue sarcoma has shown a significant reduction in tumour volume in response to the drug, with further signs of activity observed in patients WITH CANCERS NOT LIMITED TO SOFT TISSUE SARCOMA."